Surescript's EpiPen Citation 'Nothing New,' FTC Says

By Bryan Koenig · August 17, 2022, 5:30 PM EDT

The Federal Trade Commission assailed Surescripts for telling a D.C. federal judge that a Tenth Circuit decision sparing Mylan from antitrust allegations over the EpiPen bolsters Surescripts' bid to escape claims it uses exclusive...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

FEDERAL TRADE COMMISSION v. SURESCRIPTS, LLC

Case Number

1:19-cv-01080

Court

District Of Columbia

Nature of Suit

Anti-Trust

Date Filed

April 17, 2019